Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: Results of the PETACC-3 trial

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 126-132

  Klingbiel, D ^a,b   Saridaki, Z ^c,d   Roth, A D ^e   Bosman, F T ^f   Delorenzi, M ^b,f,g   Tejpar, S ^d  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g Ludwig Center for Cancer Research   (Switzerland)

Author keywords

Adjuvant treatment; Colon cancer; Microsatellite instability; Survival; Translational research

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; PROTEIN P53; SMAD4 PROTEIN; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MICROSATELLITE DNA;

ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COLON CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; COLONIC NEOPLASMS; GENETICS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; NEOPLASM RECURRENCE, LOCAL;

EID: 84922571480     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu499     Document Type: Article

References (30)

1. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
2. Thibodeau SN, French AJ, Cunningham JM et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998; 58: 1713-1718.
3. Peltomaki PT. Genetic basis of hereditary nonpolyposis colorectal carcinoma (HNPCC). Ann Med 1994; 26: 215-219.
4. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
5. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
6. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
7. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
8. Bertagnolli MM, Redston M, Compton CC et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol 2011; 29: 3153-3162.
9. Roth AD, Tejpar S, Yan P. Correlation of molecular markers in colon cancer with stage-specific prognosis: results of the translational study on the PETACC3-EORTC 40993-SAKK 60-00 trial. In ASCO Gastrointestinal Cancers Symposium (abstr 288), 2009.
10. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
11. Sinicrope FA, Foster NR, Thibodeau SN et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875.
12. Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009; 27: 15s.
13. Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007; 56: 1419-1425.
14. Bosman FT, Yan P, Tejpar S et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 2009; 15: 5528-5533.
15. Roth AD, Delorenzi M, Tejpar S et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104: 1635-1646.
16. Tejpar S, Bertagnolli M, Bosman F et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15: 390-404.
17. Gray RG, Quirke P, Handley K et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29: 4611-4619.
18. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of highdegree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-772.
19. Jover R, Zapater P, Castells A et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45: 365-373.
20. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-1821.
21. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125.
22. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
23. Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological and clinical features. Ann Oncol 2014; 25: 1995-2001.
24. French AJ, Sargent DJ, Burgart LJ et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-3415.
25. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
26. Popovici V, Budinska E, Bosman FT et al. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer 2013; 13: 439.
27. Jernvall P, Makinen MJ, Karttunen TJ et al. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 1999; 35: 197-201.
28. Sinicrope FA, Mahoney MR, Smyrk TC et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672.
29. Benson AB, III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419.
30. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 2010; 7: 174-177.